| Ticker |
LEXX
|
| CIK | 0001348362 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 100 - 740 MCCURDY ROAD, KELOWNA, A1, V1X 2P7 |
| Website | www.lexariabioscience.com |
| Phone | 250-765-6424 |
| CEO | Christopher A. Bunka |
| Employees | 7 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
LEXX: GLP-1-H25-5 Study CompleteBy John Vandermosten, CFA NASDAQ:LEXX Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that it had completed its GLP-1-H25-5 study last week and reported initial safety data. GLP-1-H25-5 was a pilot, cross-over investigation of 10 overweight volunteers that were administered oral DehydraTECH-liraglutide and Saxenda (injected liraglutide). The study was conducted to determine whether DehydraTECH Lexaria Bioscience announces completion of GLP-1-H25-5 studyLexaria Bioscience (LEXX) announced that human study GLP-1-H25-5 which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda-branded liraglutide has been completed with partial results now available.In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the world today: liraglutide, semaglutide, and tirzepatide. For liraglutide specifically, which is currently sold Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleOral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing ... Lexaria Attending BIO International ConventionBiotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that ... Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyKELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments. Lexaria previously announced, ... |
